FDAnews Drug Daily Bulletin

Acorda Reports Negative Top Line Results of Study Exploring Ampyra 5mg Efficacy

Aug. 15, 2012
A A
Acorda Therapeutics has reported negative top line results from post-marketing commitment study exploring 5mg dose of Dalfampridine-ER in multiple sclerosis (MS) patients.
Pharmaceutical Business Review